The FDA does not proactively approve drugscompanies must submit New Drug Applications with Phase 1-3 trial data meeting FDA standards
These discrepancies might be attributed to several factors, including differences in blood sample sources, medication status, disease state, sample processing methods, sample size, and the heterogeneity of OS responses across different stages of schizophrenia
Ponciano-Rodriguez, Guadalupe
While the upfront price of these drugs is high, they may save money in the long run by reducing the prevalence of obesity-related diseases, such as diabetes and heart disease, which are much more costly to treat
Bobby Hunter, UnitedHealth CEO of government programs, referenced concerns about the BALANCE program during a Tuesday morning call, stating, "We would like to find a path to yes on coverage over time, but there are some notable challenges and outstanding questions with the currently planned structure." Financial strain may have factored into insurers' decision to decline
Always talk to your healthcare provider before starting a new medication